Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT02253251
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Sponsor: MiraKind
View on ClinicalTrials.gov
Summary
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
15000
Start Date
2014-09
Completion Date
2035-09
Last Updated
2025-01-23
Healthy Volunteers
Yes
Conditions
Interventions
GENETIC
KRAS-variant and microRNA binding site mutation testing
Participant in these studies will be tested for the KRAS-variant
Locations (1)
MiraKind
Los Angeles, California, United States